<DOC>
	<DOCNO>NCT02329639</DOCNO>
	<brief_summary>Metastatic Breast cancer ( MBC ) patient ten Italian Divisions Medical Oncology , histologically confirm HER2-negative MBC , treat first-line therapy include bevacizumab 10 mg/m2 i.v . day 1 15 combine first-line paclitaxel 90 mg/m2 i.v . day 1,8 15 , every 4 week , enrol present pharmacogenetic study . MBC patient treat first-line chemotherapy include paclitaxel without bevacizumab also enrol control group .</brief_summary>
	<brief_title>Prospective Study VEGFR-2 /IL-8 Genetic Interaction MBC Treated With Paclitaxel Bevacizumab v . Chemotherapy</brief_title>
	<detailed_description>Metastatic Breast Cancer ( MBC ) patient ten Italian Divisions Medical Oncology , histologically confirm HER2-negative MBC , treat first-line therapy include bevacizumab 10 mg/m2 i.v . day 1 15 combine first-line paclitaxel 90 mg/m2 i.v . day 1,8 15 , every 4 week , enrol present pharmacogenetic study . MBC patient treat first-line chemotherapy without bevacizumab also enrol control group . Sites metastatic disease radiologically re-evaluated accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 1.1 , patient measurable disease . In patient without measurables lesion , progression disease define new lesion appear exist lesion evolve . In case non measurables lesion , deterioration clinical condition due treatment toxicity , define progression disease . Progression-free survival ( PFS ) , defined period time begin treatment first observation disease progression describe , death cause . All patient response , PFS overall survival . Each patient enter study sign inform consent . The protocol approve Ethics Committee Vast Area Northwest Tuscany ( CEAVNO ) , Pisa , Italy ( 30/04/2014 ) . Genotyping analysis blood sample ( 3 ml . ) collect ethylenediaminetetraacetic acid tube store -80Â° C. Genes polymorphism involve angiogenesis pathway already suggest predictor bevacizumab response , choose present analysis . Germline DNA extraction perform use QIamp DNA Blood Mini Kit ( Qiagen , Valencia , California , USA ) . Allelic discrimination gene perform use ABI PRISM 7900 SDS Instrument ( Applied Biosystems , Carlsbad , California , USA ) validate TaqMan single nucleotide polymorphism ( SNP ) genotyping assay ( Applied Byosistems ) . Polymerase chain reaction carry accord manufacturer 's protocol . Genotyping performed adequate number event ( &gt; 80 % study population ) report term PFS . Statistical analysis : The first aim prospective analysis evaluate possible role VEGFR-2 rs11133360/IL-8 rs4073 polymorphism genetic interaction predict bevacizumab response term PFS . The secondary end-points correlation overall survival ( OS ) response rate . All polymorphism analyze deviation Hardy-Weinberg Equilibrium ( HWE ) mean comparison observe allelic distribution expect HWE x2 test . Any correlation gene polymorphisms response rate analyze two-sided Fisher 's Exact Test . The association individual polymorphism relevant clinical-pathological characteristic PFS test use Cox proportional hazard model . The Multifactor Dimensionality Reduction ( MDR ) methodology apply ( use version 2.0 beta 6 MDR software available http : //sourceforge.net/projects/mdr/ ) investigate role interaction gene polymorphism identify biomarkers paclitaxel plus bevacizumab response . The genotype combination high PFS benefit correlate OS improvement chosen analysis . The difference PFS favourable genetic profile unfavourable genetic profile assess log-rank test kaplan-Meier method evaluate survival curve . A Cox proportional hazard model , possible genetic profile clinical pathological patient characteristic individually correlate PFS , use calculate adjust hazard ratio ( HR ) 95 % confidence interval ( 95 % CI ) . A P value &lt; 0.05 accept statistically significant . Tha Kaplan-Meier Cox proportional hazard analysis perform use SPSS version 17.0 ( SPSS , Chicago , IL ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>histologically confirm HER2negative MBC , treat firstline therapy include bevacizumab 10 mg/m2 i.v . day 1 15 combined firstline paclitaxel 90 mg/m2 i.v . day 1,8 15 , every 4 week , enrol present pharmacogenetic study . MBC patient treat firstline chemotherapy without bevacizumab also enrol control goup . histologically confirm HER2negative MBC , patient treat firstline chemotherapy without bevacizumab .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>breast cancer</keyword>
</DOC>